Search Results 1941-1950 of 13636 for monoclonal antibody

1. Study Of Nivolumab In Subjects With Relapsed Or Refractory Follicular Lymphoma (FL) (CheckMate 140) - Mayo Clinic

   ... antibody and an alkylating agent. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments ...

2. A Study To Evaluate The Safety And Efficacy Of ABT-494 For Induction And Maintenance Therapy In Subjects With Moderately To Severely Active Ulcerative Colitis - Mayo Clinic

   ... antibody (HBc Ab) positive (+) subjects (and for Hepatitis B surface antibody positive (+) subjects where mandated by local requirements);; HCV: HCV ...

3. Multiple myeloma - Doctors and departments - Mayo Clinic

   Related. Infographic: Multiple Myeloma · Measles Virus as a Cancer Fighter · Multiple myeloma. Associated Procedures. Bispecific antibody therapy · Bone marrow ...

4. NanoString GeoMx Whole Transcriptome Atlas (WTA) - Spatial Multiomics Core - Mayo Clinic Research Core Facilities

   This approach involves identifying regions of interest through morphological markers (up to three antibodies plus a nuclei stain). It's a sequencing-based ...

5. Equipment - Spatial Biology Core - Mayo Clinic Research Core Facilities

   The profiler uses unique reagents in the form of antibodies or RNA probes coupled to ultraviolet (UV) photocleavable oligonucleotide barcodes. The barcodes ...

6. Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant - Mayo Clinic

   ... antibody specific for their deceased donor. It is our hypothesis that blockade of terminal complement activation with eculizumab at the time of transplant ...

7. Multiple myeloma - Doctors and departments - Mayo Clinic

   Hematologist. Rochester, MN. Areas of focus: Amyloidosis, Multiple myeloma, Monoclonal gammopathy of undetermined significance ... Bispecific antibody therapy ...

8. A Study to Analyze CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma - Mayo Clinic

   Participation eligibility · Received treatment with a Food and Drug Administration approved PD-1 blocking antibody for 12 weeks or longer; · Have PD (according to ...

9. Publications - Jaimin S. Shah, M.D. - Mayo Clinic

   'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J ...

10. Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Serum monoclonal protein ≥ 1.0 g/dL (≥ 10 g/L) by protein electrophoresis;; ≥ 200 mg of monoclonal protein in the urine on 24-hour electrophoresis; or ...